FC
Foresite Capital Management VI LLC
13F filer · CIK 0002013341Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$643MU.S. long equity reported on 13F
Positions238 new · 2 closed
Net flow last quarter+$116MBuys minus sells
Top 10 positions weight81.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202623 positions | |||||
| $168M | 26.20% | 2.68% | +6.7% | Q4 2024 | |
| $120M | 18.60% | Not reported | Not reported | Q4 2024 | |
| $38.7M | 6.02% | 3.32% | New | Q2 2026 | |
| $35.9M | 5.59% | 0.87% | +15.4% | Q3 2025 | |
| $32.7M | 5.09% | 1.12% | +178.5% | Q1 2026 | |
| $29.1M | 4.53% | 1.32% | +49.5% | Q4 2025 | |
| $27.4M | 4.26% | 2.18% | Not reported | Q4 2024 | |
| $27.3M | 4.26% | 0.82% | New | Q2 2026 | |
| $25.3M | 3.93% | 1.52% | +198.1% | Q1 2026 | |
| $19.7M | 3.07% | 1.40% | +177.1% | Q1 2026 | |
| $18.3M | 2.85% | 1.35% | Not reported | Q2 2025 | |
| $16.8M | 2.61% | 0.18% | Not reported | Q4 2024 | |
| AATAIAtaiBeckley Inc. | $14.5M | 2.26% | 0.74% | Not reported | Q1 2026 |
| $12M | 1.87% | 3.48% | Not reported | Q2 2025 | |
| $11.3M | 1.76% | 0.32% | New | Q2 2026 | |
| $11M | 1.71% | 4.20% | -0.1% | Q1 2026 | |
| $10.5M | 1.63% | 0.62% | New | Q2 2026 | |
| $9.47M | 1.47% | 1.29% | New | Q2 2026 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $7.93M | 1.23% | 0.20% | Not reported | Q1 2026 |
| $3.21M | 0.50% | Not reported | New | Q2 2026 | |
| $2.66M | 0.41% | 0.47% | Not reported | Q1 2026 | |
| $826K | 0.13% | 0.03% | New | Q2 2026 | |
| $70.9K | 0.01% | 0.00% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202617 positions | |||||
| $150M | 32.67% | 2.52% | Not reported | Q4 2024 | |
| $93.6M | 20.33% | Not reported | Not reported | Q4 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $54.2M | 11.77% | 0.88% | Not reported | Q4 2024 |
| $26.8M | 5.82% | 2.18% | +32.6% | Q4 2024 | |
| $23.2M | 5.05% | 0.76% | +21.0% | Q3 2025 | |
| $17.8M | 3.86% | 0.88% | -0.9% | Q4 2025 | |
| $16.7M | 3.62% | 3.58% | +0.4% | Q2 2025 | |
| $12.2M | 2.65% | 0.18% | Not reported | Q4 2024 | |
| $12M | 2.60% | 4.53% | New | Q1 2026 | |
| $10M | 2.18% | 0.47% | New | Q1 2026 | |
| AATAIAtaiBeckley Inc. | $9.74M | 2.12% | 0.75% | New | Q1 2026 |
| $8.5M | 1.85% | 1.35% | +63.3% | Q2 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $7.7M | 1.67% | 0.20% | New | Q1 2026 |
| $5.99M | 1.30% | 10.57% | New | Q1 2026 | |
| $4.5M | 0.98% | 0.65% | New | Q1 2026 | |
| $4.44M | 0.96% | 0.51% | New | Q1 2026 | |
| $2.68M | 0.58% | 0.47% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 202611 positions | |||||
| $92.2M | 27.88% | 2.75% | Not reported | Q4 2024 | |
| RTRAPTRAPT Therapeutics, Inc. | $52.9M | 16.00% | 5.64% | Not reported | Q4 2024 |
| $41.5M | 12.53% | Not reported | Not reported | Q4 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $34.1M | 10.31% | 0.91% | +3.8% | Q4 2024 |
| $24.2M | 7.32% | 4.03% | +19.9% | Q2 2025 | |
| $16.5M | 4.99% | 0.64% | Not reported | Q3 2025 | |
| $15.4M | 4.66% | 0.05% | New | Q4 2025 | |
| $14.4M | 4.36% | 0.91% | New | Q4 2025 | |
| $11.4M | 3.44% | 0.18% | Not reported | Q4 2024 | |
| $10.6M | 3.21% | 1.85% | -20.2% | Q4 2024 | |
| $6.27M | 1.90% | 0.82% | Not reported | Q2 2025 | |
| Q3 2025Reported Nov 14, 202512 positions | |||||
| $89.5M | 34.57% | 2.84% | Not reported | Q4 2024 | |
| RTRAPTRAPT Therapeutics, Inc. | $40.3M | 15.57% | 9.45% | Not reported | Q4 2024 |
| CPCNTACentessa Pharmaceuticals PLC | $31.9M | 12.31% | 0.98% | +4.8% | Q4 2024 |
| $23.1M | 8.92% | 3.92% | +104.9% | Q2 2025 | |
| $16.9M | 6.55% | Not reported | Not reported | Q4 2024 | |
| $14.5M | 5.61% | 0.68% | New | Q3 2025 | |
| $12.8M | 4.93% | 2.32% | Not reported | Q4 2024 | |
| ATAKROAkero Therapeutics, Inc. | $11.6M | 4.49% | 0.31% | Not reported | Q4 2024 |
| $8.28M | 3.20% | 0.20% | Not reported | Q4 2024 | |
| $6.63M | 2.56% | 0.82% | Not reported | Q2 2025 | |
| ABRNAMAvidity Biosciences, Inc. | $1.74M | 0.67% | 0.03% | Not reported | Q2 2025 |
| CPCASIFCASI Pharmaceuticals, Inc. | $1.63M | 0.63% | 6.33% | +24.5% | Q4 2024 |
Premium opens every quarter this fund has filed